JP2014510695A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510695A5 JP2014510695A5 JP2013532004A JP2013532004A JP2014510695A5 JP 2014510695 A5 JP2014510695 A5 JP 2014510695A5 JP 2013532004 A JP2013532004 A JP 2013532004A JP 2013532004 A JP2013532004 A JP 2013532004A JP 2014510695 A5 JP2014510695 A5 JP 2014510695A5
- Authority
- JP
- Japan
- Prior art keywords
- nitro
- imidazo
- dihydro
- oxazine
- phenoxymethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 tetrahydroisoquinolinediyl Chemical group 0.000 claims description 128
- 125000000217 alkyl group Chemical group 0.000 claims description 55
- 125000003545 alkoxy group Chemical group 0.000 claims description 41
- 125000002947 alkylene group Chemical group 0.000 claims description 38
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 32
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 11
- 125000004414 alkyl thio group Chemical group 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 125000004450 alkenylene group Chemical group 0.000 claims description 8
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 8
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- HRCMXYXVAWHBTH-UHFFFAOYSA-N 2,3-dihydro-1,3-benzoxazole Chemical compound C1=CC=C2OCNC2=C1 HRCMXYXVAWHBTH-UHFFFAOYSA-N 0.000 claims description 2
- 125000004423 acyloxy group Chemical group 0.000 claims description 2
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 2
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 claims description 2
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 2
- 125000005036 alkoxyphenyl group Chemical group 0.000 claims description 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 2
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 2
- 125000004419 alkynylene group Chemical group 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000005554 pyridyloxy group Chemical group 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 2
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- RHOPXRDSDRPILC-LJQANCHMSA-N (7r)-2-nitro-7-[[2-[[4-(trifluoromethoxy)phenyl]methoxy]quinolin-6-yl]oxymethyl]-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine Chemical compound C([C@H]1CCN2C=C(N=C2O1)[N+](=O)[O-])OC(C=C1C=C2)=CC=C1N=C2OCC1=CC=C(OC(F)(F)F)C=C1 RHOPXRDSDRPILC-LJQANCHMSA-N 0.000 claims 1
- KJKCCIMKGISYLV-MUUNZHRXSA-N (7r)-2-nitro-7-[[2-[[4-[[4-(trifluoromethyl)phenyl]methoxy]phenyl]methyl]-3,4-dihydro-1h-isoquinolin-6-yl]oxymethyl]-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine Chemical compound C([C@H]1CCN2C=C(N=C2O1)[N+](=O)[O-])OC(C=C1CC2)=CC=C1CN2CC(C=C1)=CC=C1OCC1=CC=C(C(F)(F)F)C=C1 KJKCCIMKGISYLV-MUUNZHRXSA-N 0.000 claims 1
- HTIXZKRAPJDIIC-SSEXGKCCSA-N (7r)-2-nitro-7-[[4-[1-[[4-[[4-(trifluoromethoxy)phenyl]methoxy]phenyl]methyl]piperidin-4-yl]oxyphenoxy]methyl]-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine Chemical compound C([C@H]1CCN2C=C(N=C2O1)[N+](=O)[O-])OC(C=C1)=CC=C1OC(CC1)CCN1CC(C=C1)=CC=C1OCC1=CC=C(OC(F)(F)F)C=C1 HTIXZKRAPJDIIC-SSEXGKCCSA-N 0.000 claims 1
- XWQQWTLFQJHFMA-MUUNZHRXSA-N (7r)-2-nitro-7-[[4-[4-[1-[[4-(trifluoromethyl)phenyl]methyl]piperidin-4-yl]piperidin-1-yl]phenoxy]methyl]-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine Chemical compound C([C@H]1CCN2C=C(N=C2O1)[N+](=O)[O-])OC(C=C1)=CC=C1N(CC1)CCC1C(CC1)CCN1CC1=CC=C(C(F)(F)F)C=C1 XWQQWTLFQJHFMA-MUUNZHRXSA-N 0.000 claims 1
- UOCVPJPYMKKUCZ-SSEXGKCCSA-N (7r)-2-nitro-7-[[4-[4-[2-[4-[[4-(trifluoromethyl)phenyl]methoxy]phenyl]propan-2-yl]piperazin-1-yl]phenoxy]methyl]-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine Chemical compound C1CN(C=2C=CC(OC[C@@H]3OC4=NC(=CN4CC3)[N+]([O-])=O)=CC=2)CCN1C(C)(C)C(C=C1)=CC=C1OCC1=CC=C(C(F)(F)F)C=C1 UOCVPJPYMKKUCZ-SSEXGKCCSA-N 0.000 claims 1
- LTXXIPIWANUIPO-RUZDIDTESA-N (7r)-2-nitro-7-[[4-[4-[3-[3-(trifluoromethyl)phenoxy]propyl]piperidin-1-yl]phenoxy]methyl]-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine Chemical compound C([C@H]1CCN2C=C(N=C2O1)[N+](=O)[O-])OC(C=C1)=CC=C1N(CC1)CCC1CCCOC1=CC=CC(C(F)(F)F)=C1 LTXXIPIWANUIPO-RUZDIDTESA-N 0.000 claims 1
- FNYZFRPNTZOXNY-RUZDIDTESA-N (7r)-2-nitro-7-[[4-[4-[3-[4-(trifluoromethyl)phenyl]propyl]piperidin-1-yl]phenoxy]methyl]-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine Chemical compound C([C@H]1CCN2C=C(N=C2O1)[N+](=O)[O-])OC(C=C1)=CC=C1N(CC1)CCC1CCCC1=CC=C(C(F)(F)F)C=C1 FNYZFRPNTZOXNY-RUZDIDTESA-N 0.000 claims 1
- SUFXRGDFGVTLBB-OAQYLSRUSA-N (7r)-2-nitro-7-[[4-[4-[4-(trifluoromethylsulfanyl)phenoxy]piperidin-1-yl]phenoxy]methyl]-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine Chemical compound C([C@H]1CCN2C=C(N=C2O1)[N+](=O)[O-])OC(C=C1)=CC=C1N(CC1)CCC1OC1=CC=C(SC(F)(F)F)C=C1 SUFXRGDFGVTLBB-OAQYLSRUSA-N 0.000 claims 1
- BCGNVZKCAYDDIR-MUUNZHRXSA-N (7r)-2-nitro-7-[[4-[4-[4-[[4-(trifluoromethoxy)phenyl]methoxy]phenyl]piperazin-1-yl]phenoxy]methyl]-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine Chemical compound C([C@H]1CCN2C=C(N=C2O1)[N+](=O)[O-])OC(C=C1)=CC=C1N(CC1)CCN1C(C=C1)=CC=C1OCC1=CC=C(OC(F)(F)F)C=C1 BCGNVZKCAYDDIR-MUUNZHRXSA-N 0.000 claims 1
- QPGHIZAPZQVXFZ-HSZRJFAPSA-N (7r)-2-nitro-7-[[4-[4-[[4-(trifluoromethoxy)phenyl]methyl]piperidin-1-yl]phenoxy]methyl]-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine Chemical compound C([C@H]1CCN2C=C(N=C2O1)[N+](=O)[O-])OC(C=C1)=CC=C1N(CC1)CCC1CC1=CC=C(OC(F)(F)F)C=C1 QPGHIZAPZQVXFZ-HSZRJFAPSA-N 0.000 claims 1
- WAUIWMWBDVMUSM-OBFZPWGMSA-N (7r)-2-nitro-7-[[4-[4-[[4-(trifluoromethyl)cyclohexyl]methyl]piperazin-1-yl]phenoxy]methyl]-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine Chemical compound C([C@H]1CCN2C=C(N=C2O1)[N+](=O)[O-])OC(C=C1)=CC=C1N(CC1)CCN1CC1CCC(C(F)(F)F)CC1 WAUIWMWBDVMUSM-OBFZPWGMSA-N 0.000 claims 1
- DPRJLOBFJWBPTQ-GDLZYMKVSA-N (7r)-2-nitro-7-[[4-[4-[[4-[4-(trifluoromethoxy)phenoxy]phenyl]methyl]piperidin-1-yl]phenoxy]methyl]-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine Chemical compound C([C@H]1CCN2C=C(N=C2O1)[N+](=O)[O-])OC(C=C1)=CC=C1N(CC1)CCC1CC(C=C1)=CC=C1OC1=CC=C(OC(F)(F)F)C=C1 DPRJLOBFJWBPTQ-GDLZYMKVSA-N 0.000 claims 1
- FDBVQXYMWRGACY-GDLZYMKVSA-N (7r)-2-nitro-7-[[4-[4-[[4-[[4-(trifluoromethyl)phenyl]methoxy]phenyl]methyl]piperazin-1-yl]phenoxy]methyl]-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine Chemical compound C([C@H]1CCN2C=C(N=C2O1)[N+](=O)[O-])OC(C=C1)=CC=C1N(CC1)CCN1CC(C=C1)=CC=C1OCC1=CC=C(C(F)(F)F)C=C1 FDBVQXYMWRGACY-GDLZYMKVSA-N 0.000 claims 1
- KWPFAJJLPVFSAP-WVXBCFDCSA-N (7r)-7-[[4-[(3r)-3-methyl-4-[[4-[[4-(trifluoromethyl)phenyl]methoxy]phenyl]methyl]piperazin-1-yl]phenoxy]methyl]-2-nitro-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine Chemical compound C([C@H]1C)N(C=2C=CC(OC[C@@H]3OC4=NC(=CN4CC3)[N+]([O-])=O)=CC=2)CCN1CC(C=C1)=CC=C1OCC1=CC=C(C(F)(F)F)C=C1 KWPFAJJLPVFSAP-WVXBCFDCSA-N 0.000 claims 1
- UBSXNNFCLZZKIX-JOCHJYFZSA-N (7r)-7-[[4-[4-methoxy-4-[4-(trifluoromethyl)phenyl]piperidin-1-yl]phenoxy]methyl]-2-nitro-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine Chemical compound C1CN(C=2C=CC(OC[C@@H]3OC4=NC(=CN4CC3)[N+]([O-])=O)=CC=2)CCC1(OC)C1=CC=C(C(F)(F)F)C=C1 UBSXNNFCLZZKIX-JOCHJYFZSA-N 0.000 claims 1
- FNYJTYRLLXMNFQ-LJAQVGFWSA-N (7s)-2-nitro-7-[[4-[4-[[4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl]methyl]phenyl]phenoxy]methyl]-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine Chemical compound C([C@@H]1CCN2C=C(N=C2O1)[N+](=O)[O-])OC(C=C1)=CC=C1C(C=C1)=CC=C1CN(CC1)CCC1OC1=CC=C(OC(F)(F)F)C=C1 FNYJTYRLLXMNFQ-LJAQVGFWSA-N 0.000 claims 1
- WNCCYOQDKJZVBP-OAQYLSRUSA-N 1-[4-[4-[[(7r)-2-nitro-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazin-7-yl]methoxy]phenyl]phenyl]-4-(trifluoromethyl)piperidin-4-ol Chemical compound C1CC(O)(C(F)(F)F)CCN1C1=CC=C(C=2C=CC(OC[C@@H]3OC4=NC(=CN4CC3)[N+]([O-])=O)=CC=2)C=C1 WNCCYOQDKJZVBP-OAQYLSRUSA-N 0.000 claims 1
- GWTGPIFIJCPKNL-UHFFFAOYSA-N 2-nitro-7-[[1-[3-[4-(trifluoromethoxy)phenoxy]propyl]-3,4-dihydro-2h-quinolin-6-yl]oxymethyl]-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine Chemical compound O1C2=NC([N+](=O)[O-])=CN2CCC1COC(C=C1CCC2)=CC=C1N2CCCOC1=CC=C(OC(F)(F)F)C=C1 GWTGPIFIJCPKNL-UHFFFAOYSA-N 0.000 claims 1
- SBFDEKAGNIJSMQ-UHFFFAOYSA-N 2-nitro-7-[[4-[1-[[4-(trifluoromethoxy)phenyl]methyl]piperidin-4-yl]phenoxy]methyl]-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine Chemical compound O1C2=NC([N+](=O)[O-])=CN2CCC1COC(C=C1)=CC=C1C(CC1)CCN1CC1=CC=C(OC(F)(F)F)C=C1 SBFDEKAGNIJSMQ-UHFFFAOYSA-N 0.000 claims 1
- CALBGXXQKYNRLO-UHFFFAOYSA-N 2-nitro-7-[[4-[2-[4-(trifluoromethoxy)phenyl]-1,3-thiazol-4-yl]phenoxy]methyl]-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine Chemical compound O1C2=NC([N+](=O)[O-])=CN2CCC1COC(C=C1)=CC=C1C(N=1)=CSC=1C1=CC=C(OC(F)(F)F)C=C1 CALBGXXQKYNRLO-UHFFFAOYSA-N 0.000 claims 1
- AXSGSFPUZALTPB-UHFFFAOYSA-N 2-nitro-7-[[4-[2-[[4-(trifluoromethoxy)phenoxy]methyl]-1,3-oxazol-4-yl]phenoxy]methyl]-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine Chemical compound O1C2=NC([N+](=O)[O-])=CN2CCC1COC(C=C1)=CC=C1C(N=1)=COC=1COC1=CC=C(OC(F)(F)F)C=C1 AXSGSFPUZALTPB-UHFFFAOYSA-N 0.000 claims 1
- SXCVNTHRLFSBOY-UHFFFAOYSA-N 2-nitro-7-[[4-[4-[3-[4-[4-(trifluoromethoxy)phenoxy]phenyl]propyl]piperazin-1-yl]phenoxy]methyl]-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine Chemical compound O1C2=NC([N+](=O)[O-])=CN2CCC1COC(C=C1)=CC=C1N(CC1)CCN1CCCC(C=C1)=CC=C1OC1=CC=C(OC(F)(F)F)C=C1 SXCVNTHRLFSBOY-UHFFFAOYSA-N 0.000 claims 1
- ABFDBSSJEQJATF-UHFFFAOYSA-N 2-nitro-7-[[4-[4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl]phenoxy]methyl]-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine Chemical compound O1C2=NC([N+](=O)[O-])=CN2CCC1COC(C=C1)=CC=C1N(CC1)CCC1OC1=CC=C(OC(F)(F)F)C=C1 ABFDBSSJEQJATF-UHFFFAOYSA-N 0.000 claims 1
- NEDDDYNVZBXBMF-UHFFFAOYSA-N 2-nitro-7-[[4-[4-[[4-(trifluoromethoxy)phenyl]methyl]piperazin-1-yl]phenoxy]methyl]-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine Chemical compound O1C2=NC([N+](=O)[O-])=CN2CCC1COC(C=C1)=CC=C1N(CC1)CCN1CC1=CC=C(OC(F)(F)F)C=C1 NEDDDYNVZBXBMF-UHFFFAOYSA-N 0.000 claims 1
- XICRSBZYTPYINV-UHFFFAOYSA-N 2-nitro-7-[[6-[4-[2-[4-(trifluoromethoxy)phenoxy]ethyl]piperidin-1-yl]pyridin-3-yl]oxymethyl]-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine Chemical compound O1C2=NC([N+](=O)[O-])=CN2CCC1COC(C=N1)=CC=C1N(CC1)CCC1CCOC1=CC=C(OC(F)(F)F)C=C1 XICRSBZYTPYINV-UHFFFAOYSA-N 0.000 claims 1
- 125000001318 4-trifluoromethylbenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C(F)(F)F 0.000 claims 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims 1
- GGMZNCHFQWBFFQ-UHFFFAOYSA-N 7-[[3-fluoro-4-[4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl]phenoxy]methyl]-2-nitro-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine Chemical compound O1C2=NC([N+](=O)[O-])=CN2CCC1COC(C=C1F)=CC=C1N(CC1)CCC1OC1=CC=C(OC(F)(F)F)C=C1 GGMZNCHFQWBFFQ-UHFFFAOYSA-N 0.000 claims 1
- FYNAXAJOXWPULF-UHFFFAOYSA-N 7-methyl-2-nitro-7-[[4-[4-[2-[4-(trifluoromethoxy)phenyl]ethyl]piperidin-1-yl]phenoxy]methyl]-5,6-dihydroimidazo[2,1-b][1,3]oxazine Chemical compound C1CN2C=C([N+]([O-])=O)N=C2OC1(C)COC(C=C1)=CC=C1N(CC1)CCC1CCC1=CC=C(OC(F)(F)F)C=C1 FYNAXAJOXWPULF-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 description 15
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 3
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161476003P | 2011-04-15 | 2011-04-15 | |
| US61/476,003 | 2011-04-15 | ||
| PCT/JP2012/060645 WO2012141338A1 (en) | 2011-04-15 | 2012-04-13 | 6,7 - dihydroimidazo [2, 1 - b] [1, 3] oxazine bactericides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014510695A JP2014510695A (ja) | 2014-05-01 |
| JP2014510695A5 true JP2014510695A5 (enExample) | 2015-05-28 |
| JP5916739B2 JP5916739B2 (ja) | 2016-05-11 |
Family
ID=46168570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013532004A Expired - Fee Related JP5916739B2 (ja) | 2011-04-15 | 2012-04-13 | ６，７−ジヒドロイミダゾ［２，１−ｂ］［１，３］オキサジン化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9051333B2 (enExample) |
| EP (1) | EP2697232B1 (enExample) |
| JP (1) | JP5916739B2 (enExample) |
| CN (1) | CN103596960B (enExample) |
| WO (1) | WO2012141338A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR101704A1 (es) | 2014-08-28 | 2017-01-04 | Otsuka Pharma Co Ltd | Compuestos heterocíclicos fusionados |
| WO2016107602A1 (zh) * | 2015-01-01 | 2016-07-07 | 成都贝斯凯瑞生物科技有限公司 | 一类取代氮杂环衍生物及其应用 |
| CN107207532B (zh) * | 2015-01-29 | 2019-07-30 | 南京明德新药研发股份有限公司 | 抗肺结核病的硝基咪唑衍生物 |
| JP6905506B2 (ja) * | 2016-02-26 | 2021-07-21 | 大塚製薬株式会社 | ピペリジン誘導体 |
| RU2657168C2 (ru) * | 2016-04-29 | 2018-06-08 | Общество с ограниченной ответственностью "Общество Сферического Кино" | Программно-аппаратный комплекс для автоматической калибровки многопроекторных систем с возможностью воспроизводить контент в высоком разрешении с использованием средств шифрования и цифровой дистрибьюции, способ шифрования контента для использования в способе воспроизведения контента |
| WO2019128963A1 (zh) * | 2017-12-26 | 2019-07-04 | 南京明德新药研发股份有限公司 | 抗肺结核病的硝基咪唑衍生物 |
| EP3908578A4 (en) * | 2019-01-08 | 2023-03-08 | B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University | ANTIMICROBIAL COMPOUNDS AND COMPOSITIONS THEREOF |
| EP3936192B1 (en) | 2019-03-06 | 2025-04-09 | Daiichi Sankyo Company, Limited | Pyrrolopyrazole derivative |
| CN110452188A (zh) * | 2019-09-12 | 2019-11-15 | 蚌埠学院 | 一种伏硫西汀的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07330B2 (ja) | 1991-07-06 | 1995-01-11 | 日精樹脂工業株式会社 | 駆動装置 |
| US5668127A (en) * | 1995-06-26 | 1997-09-16 | Pathogenesis Corporation | Nitroimidazole antibacterial compounds and methods of use thereof |
| TWI347946B (en) | 2002-10-11 | 2011-09-01 | Otsuka Pharma Co Ltd | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound |
| AU2004285811B2 (en) | 2003-10-31 | 2008-06-12 | Otsuka Pharmaceutical Co., Ltd. | 2,3-dihydro-6-nitroimidazo (2,1-B) oxazole compounds for the treatment of tuberculosis |
| JP4761756B2 (ja) | 2003-10-31 | 2011-08-31 | 大塚製薬株式会社 | ２，３−ジヒドロイミダゾ［２，１−ｂ］オキサゾ−ル化合物 |
| CN101965353B (zh) * | 2008-03-26 | 2014-12-17 | 丹诺医药(苏州）有限公司 | 共价连接到取代苯基噁唑烷酮的双环硝基咪唑类 |
| BR112012002278A2 (pt) * | 2009-07-31 | 2020-09-15 | Global Alliance For Tb Drug Development | nitroimidazo-oxazinas e seus usos na terapia antitubercular |
| RU2540860C2 (ru) * | 2009-07-31 | 2015-02-10 | Глоубал Элаенс Фор Тб Драг Дивелопмент | Нитроимидазооксазиновые и нитроимидазооксазольные аналоги и их применение |
-
2012
- 2012-04-13 JP JP2013532004A patent/JP5916739B2/ja not_active Expired - Fee Related
- 2012-04-13 EP EP12723752.7A patent/EP2697232B1/en not_active Not-in-force
- 2012-04-13 US US14/111,262 patent/US9051333B2/en not_active Expired - Fee Related
- 2012-04-13 CN CN201280029213.6A patent/CN103596960B/zh not_active Expired - Fee Related
- 2012-04-13 WO PCT/JP2012/060645 patent/WO2012141338A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014510695A5 (enExample) | ||
| JP6193922B2 (ja) | ハロアルキルヘテロアリールベンズアミド化合物 | |
| US6090807A (en) | Use of heterocyclic compounds | |
| JP2015501799A5 (enExample) | ||
| KR101286499B1 (ko) | 신경치료용 아졸 화합물 | |
| KR20160033726A (ko) | 헤테로방향족 고리-벤질-아미드-사이클 코어를 포함하는 오토탁신 억제제 | |
| JP5792173B2 (ja) | ｍＧｌｕＲ５ネガティブアロステリックモジュレータとしての置換ヘテロアリールアミド類似体、ならびに、その形成方法および使用方法 | |
| AU2007235577B2 (en) | Benzoimidazol-2-yl pyridines as modulators of the histamine H4 receptor | |
| RU2009148673A (ru) | Производные пиразинона и их применение для лечения легочных заболеваний | |
| JP2012508274A5 (enExample) | ||
| JP2018519323A5 (enExample) | ||
| JP2008536825A5 (enExample) | ||
| JP2002502844A5 (enExample) | ||
| JP2008533151A5 (enExample) | ||
| CO6150176A2 (es) | Derivados de bencimidazol utiles en el tratamiento de los trastornos relacionados con el receptor vaniloide trpv1 | |
| JP2020531454A (ja) | ｍＧＬｕＲ４アロステリック増強剤としてのインダゾール化合物、組成物、および神経機能不全を治療する方法 | |
| JP2005500276A5 (enExample) | ||
| JP2017500321A5 (enExample) | ||
| JP2012527487A5 (enExample) | ||
| KR101659982B1 (ko) | 페닐 피페라진 화합물, 이를 포함하는 약학적 조성물 및 그 용도 | |
| JP2009501745A5 (enExample) | ||
| ME02167B (me) | Piridinil- i pirazinil-metiloksi-aril derivati korisni kao inhibitori tirozin kinaze slezine (syk) | |
| JP2011519845A5 (enExample) | ||
| WO2008101195A4 (en) | Drug resistance reversal in neoplastic disease | |
| JP2008533063A5 (enExample) |